Literature DB >> 33263511

Frequency of and risk factors for carbapenem-resistant Enterobacteriaceae.

Katie E Barber1, Jamie L Wagner1, Rachel C Larry1, Kayla R Stover1.   

Abstract

Introduction. Carbapenem-resistant Enterobacteriaceae (CRE) are an urgent threat in the USA and are associated with adverse clinical and economic outcomes. Several studies have evaluated risk factors for acquiring CRE versus carbapenem-susceptible Enterobacteriaceae, identifying antibiotic use and length of hospital stay as major players. However, no studies have compared risk factors for CRE colonization versus infection.Hypothesis/Gap Statement. Patients with CRE infection will have different risk factors and worse clinical outcomes than patients with CRE colonization.Aim. To assess clinical outcomes in patients with CRE infection versus CRE colonization.Methodology. A retrospective cohort of adult patients admitted between 1 June 2013 and 31 July 2018 with the first positive CRE culture from any source was performed. Patients were divided into two groups: CRE infection versus CRE colonization. Data collected included demographics, comorbidities, past antimicrobial usage and clinical outcomes (length of stay, in-hospital mortality). The primary outcome was infection-related length of stay. Data analysis was performed utilizing SPSS with a two-sided P value of less than 0.05 considered statistically significant.Results. A total of 56 patients were included (32 with infection; 24 with colonization). Baseline characteristics were similar between both groups. Infected patients were more likely to have higher actual body weight compared to colonized patients (P=0.03). CRE-infected patients had a longer infection-related hospital stay [12 days (5-20) and 7.5 days (1-13), respectively; P=0.08], but in-hospital mortality was similar between infected and colonized patients (37.5 and 29.2 %, respectively; P=0.30). Patients with infection were more likely to have previous exposure to levofloxacin (P=0.02) and trimethoprim/sulfamethoxazole (P=0.03) for a median of 9 days compared to those with colonization. The most common source of CRE in infected patients was the blood compared to respiratory sources in colonized patients.Conclusion. CRE infection as opposed to colonization was more common in patients with previous exposure to levofloxacin and trimethoprim/sulfamethoxazole and those with higher actual body weight.

Entities:  

Keywords:  CRE; Enterobacteriaceae; obesity

Mesh:

Substances:

Year:  2021        PMID: 33263511      PMCID: PMC8131018          DOI: 10.1099/jmm.0.001286

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  15 in total

1.  The Likelihood of Developing a Carbapenem-Resistant Enterobacteriaceae Infection during a Hospital Stay.

Authors:  Pranita D Tamma; Abida Kazmi; Yehudit Bergman; Katherine E Goodman; Ernest Ekunseitan; Joe Amoah; Patricia J Simner
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Determining the Utility of Methicillin-Resistant Staphylococcus aureus Nares Screening in Antimicrobial Stewardship.

Authors:  Kari A Mergenhagen; Kaitlyn E Starr; Bethany A Wattengel; Alan J Lesse; Zarchi Sumon; John A Sellick
Journal:  Clin Infect Dis       Date:  2020-08-22       Impact factor: 9.079

3.  Prevalence and risk factors for acquisition of carbapenem-resistant Enterobacteriaceae in the setting of endemicity.

Authors:  Mahesh Swaminathan; Saarika Sharma; Stephanie Poliansky Blash; Gopi Patel; David B Banach; Michael Phillips; Vincent LaBombardi; Karen F Anderson; Brandon Kitchel; Arjun Srinivasan; David P Calfee
Journal:  Infect Control Hosp Epidemiol       Date:  2013-06-11       Impact factor: 3.254

4.  Risk factors for carbapenem-resistant Enterobacteriaceae infections: a French case-control-control study.

Authors:  Marie-Hélène Nicolas-Chanoine; Marie Vigan; Cédric Laouénan; Jérôme Robert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-11-28       Impact factor: 3.267

5.  The role of colonization pressure in the dissemination of colistin or tigecycline resistant KPC-producing Klebsiella pneumoniae in critically ill patients.

Authors:  M Papadimitriou-Olivgeris; M Christofidou; F Fligou; C Bartzavali; T Vrettos; K S Filos; M Marangos; E D Anastassiou
Journal:  Infection       Date:  2014-07-10       Impact factor: 3.553

6.  A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies.

Authors:  Maria J G T Vehreschild; Axel Hamprecht; Lisa Peterson; Sören Schubert; Maik Häntschel; Silke Peter; Philippe Schafhausen; Holger Rohde; Marie V Lilienfeld-Toal; Isabelle Bekeredjian-Ding; Johannes Libam; Martin Hellmich; Jörg J Vehreschild; Oliver A Cornely; Harald Seifert
Journal:  J Antimicrob Chemother       Date:  2014-08-06       Impact factor: 5.790

7.  Multicenter Study of the Risk Factors for Colonization or Infection with Carbapenem-Resistant Enterobacteriaceae in Children.

Authors:  Kathleen Chiotos; Pranita D Tamma; Kelly B Flett; Matthew Naumann; Manjiree V Karandikar; Warren B Bilker; Theoklis Zaoutis; Jennifer H Han
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

8.  Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis.

Authors:  Marya D Zilberberg; Brian H Nathanson; Kate Sulham; Weihong Fan; Andrew F Shorr
Journal:  BMC Infect Dis       Date:  2017-04-17       Impact factor: 3.090

9.  Using Patient Risk Factors to Identify Whether Carbapenem-Resistant Enterobacteriaceae Infections Are Caused by Carbapenemase-Producing Organisms.

Authors:  Patricia J Simner; Katherine E Goodman; Karen C Carroll; Anthony D Harris; Jennifer H Han; Pranita D Tamma
Journal:  Open Forum Infect Dis       Date:  2018-05-17       Impact factor: 3.835

10.  Risk Factors for Carbapenem-Resistant Klebsiella pneumoniae Infection: A Meta-Analysis.

Authors:  Pin Liu; Xuan Li; Mei Luo; Xuan Xu; Kewen Su; Shuai Chen; Ying Qing; Yingli Li; Jingfu Qiu
Journal:  Microb Drug Resist       Date:  2017-07-27       Impact factor: 3.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.